Shield Sets New Industry Standard for Data Integrity with Customer Visibility at Every Stage
8.10.2025 12:00:00 CEST | Business Wire | Press release
Native AI-powered platform delivers zero gap data integrity with unprecedented visibility and accessibility throughout the entire data lifecycle
Shield, the industry's most comprehensive digital communications governance and archiving (DCGA) platform and Gartner-categorized Visionary, today announced a new data approach that provides gold-standard clarity and control across the full data lifecycle. Shield’s new data process is designed to free institutions from data pipeline opacity and blind spots through zero-gap ingestion, full transparency, and full data accessibility at every stage of its lifecycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008306749/en/

Product UI showing ingestion reporting.
Regulators are placing increasing scrutiny on data completeness and accessibility, adding pressure to already overworked compliance teams. The stakes are significant: The average cost of noncompliance exceeded $4.88 million per incident in 2024, according to Gartner. This growing compliance burden is reflected in recent research by GreySpark, which found that 83% of surveyed global banks reported data issues in capture, retention, and auditability. Financial firms struggle with fragmented systems that create compliance vulnerabilities and operational inefficiencies. Even minor gaps in data completeness early on can lead to significant downstream impact across a firm’s risk management, including stalled insights, eroded trust, missed regulatory requirements, all of which create vulnerability to significant fines.
“Shield is helping the world’s leading financial institutions break through legacy barriers and fragmented data by unifying the full communications lifecycle,” said Tamar Sharir Beiser, Chief Product Officer at Shield. “With our transparent, AI-powered platform, firms gain complete data integrity, eliminate blind spots, and respond to regulatory demands with confidence. For too long, organizations have struggled with limited visibility into their data. Shield is changing that by setting a new standard of clarity, with a fully unified data flow, transparency, and accessibility at every stage of the lifecycle.”
Unified End-to-End Data Lifecycle Approach
Shield's native end-to-end DCGA platform handles the complete data lifecycle from capture through archiving, delivering clarity and trust across the entire data process.
At the heart of Shield’s new standard are three key pillars:
- Zero data loss: Comprehensive monitoring and validation ensures no communication escapes capture, with real-time alerts when issues arise so that institutions can meet strict traceability and completeness standards with confidence.
- Complete transparency: Full visibility into data status at every stage enables proactive compliance management and audit readiness. Unmatched completeness reporting, with built-in granularity and flexibility, helps compliance teams spot gaps early and stay audit-ready.
- Advanced customer access: Instant access to data with no vendor lag, exit fees, or hidden costs. Flexible exports can be run on demand or scheduled through UI or API, across metadata, audit trails, alerts, and communications.
“With Shield’s new data integrity capabilities, we’ve been able to close audit findings and mature our reconciliation process. The access to dedicated reporting metrics gives us the confidence that our data integrity is intact, and that we can demonstrate compliance with clarity.” - IT Project Lead, Global Wealth Fund
Shield’s robust technological data approach is backed by real-time human monitoring and proactive anomaly resolution. With data at its core, Shield’s platform provides a single source of truth across the portfolio of products, working in tandem with Shield Archive for secure retention and preservation of original communications. This unified, scalable framework supports firm-specific data needs and regulatory obligations with self-service visibility and full chain of custody for verifiable evidence at every stage.
For more information about Shield’s robust new data offering, please contact Shield directly at shieldfc.com/contact.
About Shield
Shield is the industry's most comprehensive digital communications governance and archiving solution—purpose-built for financial institutions. Trusted by a third of the world’s leading financial institutions, Shield is named by Gartner as a Visionary in the Digital Communication Governance and Archiving sector. Shield's platform combines industry-leading AI-powered innovation with deep regulatory expertise to strengthen compliance, intuitively, efficiently, and securely. Learn more at shieldfc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251008306749/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom